세계의 수의 종양학 시장 평가 : 동물 유형별, 치료법별, 암 유형별, 지역별 - 기회 및 예측(2018-2032년)

Global veterinary oncology market is projected to witness a CAGR of 7.63% during the forecast period 2025-2032, growing from USD 1.01 billion in 2024 to USD 1.82 billion in 2032. The veterinary oncology market is experiencing rapid growth due to aging pets experience higher cancer incidence, owners embrace "pet-as-family" mindsets, and insurers broaden coverage for sophisticated procedures. According to the American Veterinary Medical Association, about 1 in 4 dogs experience cancer during their lifespan, and almost half of dogs over the age of 10 will experience cancer development.

The veterinary oncology field specializes in detecting and treating cancer, along with cancer prevention strategies for animals. Veterinary oncologists diagnose diseases including skin tumors, lymphoma, and mammary gland tumors, and use surgery together with chemotherapy and radiation therapy, and immunotherapy for their treatment. Professionals in this specialty deliver superior results by combining therapeutic approaches with early disease detection and proper disease staging, and the development of individualized treatment plans.

The improved medical care of pets leads to extended lifespans and an increased number of cancer diagnoses in animals. The improved imaging technology, together with improved chemotherapy and targeted radiation methods, makes cancer treatment in animals more straightforward and effective. Pet owners now seek special medical attention for their animals because they better understand their pets' health needs, and they have the financial means to pursue it. The pharmaceutical industry produces multiple animal-specific cancer medicines, which lead to improved survival rates, together with enhanced quality of life for pets.

For instance, in November 2023, TheraVet specialized in providing osteoarticular disease treatments for pets. The company has launched a clinical study to assess the therapeutic value of BIOCERA-VET Osteosarcoma Cementoplasty used together with Stereotactic Radiotherapy (SRT) for pets diagnosed with osteosarcoma.

Rising Cancer Prevalence in Animals Boosts Global Veterinary Oncology Market Demand

Animal cancer incidence rates are rising, which drives higher demand for veterinary oncology services. Better healthcare services extend pet lifespans, thus leading to an increased occurrence of age-related cancer cases. The rising number of pet owners and growing animal health awareness generates a strong need for early cancer detection, which results in more screening services and chemotherapy and radiation therapy, along with immunotherapy treatment choices. Modern veterinary clinics use advanced diagnostic equipment and better imaging methods and biopsy procedures to detect cancer earlier while maintaining higher levels of accuracy. Also, pharmaceutical companies advancing targeted therapies for pets drive ongoing market expansion. The veterinary oncology sector achieves rapid progress in treatment alternatives and diagnostic tools due to increasing pet owner investment in premium medical care. Developed regions lead market expansion, which expands globally through infrastructure development in emerging economies, together with rising pet ownership rates.

Additionally, to address the rising cases of cancer in animals and the growing pet ownership, companies are launching new drugs for the treatment of cancer to improve the quality of life. For instance, in March 2025, Privo Technologies Inc. leads as an innovative biopharmaceutical organization that launched BeneVet Oncology to enhance companion animal health. BeneVet utilizes Privo's state-of-the-art drug delivery systems to meet veterinary medical requirements that currently lack solutions.

Technological Advancements in Diagnosis and Treatments Surged Market Growth

The veterinary oncology market is experiencing remarkable growth due to advancements in medical technology for both diagnosis and treatment methods. Modern imaging methods, such as MRI, CT scans, and PET scans, allow precise and early detection in animals. The use of molecular diagnostics and liquid biopsies allows veterinarians to perform non-invasive tumor profiling, which results in better individualized treatment approaches. Targeted drugs work effectively with immunotherapy and monoclonal antibodies to improve patient outcomes and decrease side effects relative to standard chemotherapy approaches. Stereotactic radiosurgery represents the current standard of modern radiation therapy because it allows precise tumor destruction while protecting healthy tissue from harm. The market is experiencing growth because veterinary oncology treatment accessibility improves through telemedicine and AI diagnostic systems. The market expansion receives financial backing through increasing pet populations, together with enhanced knowledge about animal cancer therapy choices. Veterinary research institutes collaborate with pharmaceutical companies that receive regulatory approvals to develop new oncology drugs for their investment. Veterinary oncology receives a market boost from technological and therapeutic advancements, which lead to improved results for both pets and livestock.

For instance, in January 2023, VolitionRx Limited operated as a global epigenetics business that declares its Nu. Q Vet Cancer Test is available for veterinarian pre-orders through Heska Corporation, which delivers rapid, accurate, low-cost, and simple on-site testing solutions to veterinary clinics for improved clinical decisions and better patient results.

Investment in Research and Development Support Market Expansion

Research and development (R&D) investment serves as a fundamental component that expands the veterinary oncology market growth. Pet cancer diagnostics, together with targeted therapies and immunotherapies, are experiencing growth because pharmaceutical companies and academic institutions are increasing their funding. Research and development activities work to produce new treatments while enhancing diagnostic methods and creating better personalized medical approaches for animals with cancer. The increasing number of pet cancer cases, combined with rising pet ownership and increasing veterinary care spending, supports market expansion. The fast development of innovation results from partnerships between veterinary oncologists and biotechnology companies, together with research institutions. The progress of veterinary oncology receives support from government funding and private sector investments, which result in improved treatment outcomes. The veterinary oncology market will experience substantial growth through ongoing R&D development to deliver fresh therapeutic alternatives that enhance animal quality of life. The veterinary cancer research sector needs continuous investment because it generates market growth opportunities for pharmaceutical companies and diagnostic laboratories, and veterinary clinics.

For instance, in January 2024, Morris Animal Foundation announced the selection of eight new grant recipients who advance the Foundation's commitment to improving the lives of dogs suffering from cancer through pioneering research initiatives. The veterinary oncology industry experiences substantial expansion because of ongoing R&D projects, together with industry stakeholder investments during the next several years.

Canine Holds Largest Market Share in Veterinary Oncology

The veterinary cancer market maintains its largest portion through canines because dogs demonstrate a strong cancer tendency that leads to frequent lymphoma, mast cell tumors, and osteosarcoma diagnoses. Advanced diagnostic tools and treatment methods derived from human chemotherapy protocols and stereotactic radiation, and the development of immunotherapy, have increased therapeutic possibilities, which expand the market. The market expansion results from three main factors: longer pet life spans and increased owner funding of specialized cancer treatments, and ongoing research into breed-specific oncogenetics. The field of veterinary oncology benefits from comparative oncology, as canine cancers serve as effective models for human cancers, attracting research funding from both veterinary and biomedical institutions. The veterinary oncology field continues to advance through pharmaceutical innovation, which develops targeted therapies and combination protocols that enhance treatment success, thus making canine oncology a leading veterinary specialty and an expanding sector in animal health.

For instance, in August 2024, Purdue University, together with Akston Biosciences, established a strategic agreement to develop an anti-cPD-L1 monoclonal antibody (mAb) immunotherapy for canine cancer treatment. The businesses creating immunotherapeutic veterinary cancer therapies contribute to expanding the total market size.

North America Dominates the Veterinary Oncology Market Size

North America dominates the veterinary oncology market due to its large pet population and superior medical facilities, and substantial financial support for animal healthcare. The United States and Canada maintain an advanced veterinary market that operates oncology clinics to provide innovative treatments, including chemotherapy, together with radiation therapy and immunotherapy. The rising awareness of pet cancer and the growing humanization of animals has driven demand for advanced diagnostic procedures and treatment options. High disposable income levels of pet owners enable them to pay for costly medical treatments. The rising number of pet insurance policies enables pet owners to obtain expensive cancer treatment options. North America enjoys strong R&D activities because the leading pharmaceutical companies and academic institutions conduct innovative research on veterinary cancer care. The market expands because of supportive government regulations, together with funding programs dedicated to animal health research. The North American veterinary oncology market leads globally because Zoetis and Elanco serve as major market players. North America continues to dominate the worldwide veterinary oncology market due to multiple factors, which include expanding pet healthcare funding and technological progress.

For instance, in January 2025, IDEXX Laboratories, Inc., introduced IDEXX Cancer Dx as the first lymphoma detection diagnostic panel, which particularly serves the 20 million North American dogs at increased cancer risk. Veterinarians across the United States may now access IDEXX Cancer Dx for USD15, which enables them to add the blood test to sick pet panels or annual wellness screenings and receive actionable results within 2 to 3 days.

Impact of U.S. Tariffs on Global Veterinary Oncology Market

The U.S. tariffs implemented on imported goods, including medical supplies and pharmaceuticals, will create substantial effects on veterinary oncology markets through increased costs for both veterinary clinics and pet owners. Advanced cancer treatments, including radiation therapy machines together with chemotherapy drugs and specialized diagnostics, depend on imported components or finished products that experience tariffs. The increased prices resulting from tariffs will make advanced treatments less affordable, which restricts pet access and slows market expansion. The application of tariffs to protect domestic producers leads to increased manufacturing costs, which forces businesses to raise product prices. Veterinary clinics with constrained budgets choose between postponing equipment upgrades and purchasing lower-quality solutions, which slows down cancer advancement in veterinary medicine. The implementation of tariffs to defend domestic industries generates unforeseen problems that restrict vital animal treatments, thus decreasing the quality of veterinary cancer care across the United States.

Key Players Landscape and Outlook

Industry leaders enhance their position because of technological advancements, together with strategic business relationships and growing market needs. They develop their business through company combinations and worldwide expansion by using research and development to maintain their competitive position. The adoption of artificial intelligence, together with automation and sustainable business practices, helps these organizations protect their future operations. Digital transformation investments, along with customer-centric solutions, create sustainable long-term business expansion. Companies maintain their market strength by developing scalable operations together with adaptable methods and investing in their workforce. They maintain their market leadership by using data-driven choices while building partnerships with other businesses and developing business models that challenge traditional approaches. The future looks promising for businesses that adopt transformation, but they need flexible approaches to maintain their leadership and innovation because of regulatory and economic obstacles.

In September 2024, Boehringer Ingelheim International GmbH finished its purchase of Saiba Animal Health AG to broaden its range of animal therapeutic products. The company's innovative vaccine development platform is expected to enhance the veterinary oncology sector.

In March 2024, Merck & Co. Inc. finished the purchase of Harpoon Therapeutics, Inc., to strengthen our oncology pipeline through cutting-edge solutions that serve cancer patients throughout the world. Following the purchase, Harpoon became a fully owned subsidiary of Merck while its common shares stopped trading on the Nasdaq Stock Market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Veterinary Oncology Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Animal Type
    • 5.2.1.1. Canine
    • 5.2.1.2. Feline
    • 5.2.1.3. Equine
    • 5.2.1.4. Others
  • 5.2.2. By Therapy
    • 5.2.2.1. Radiotherapy
      • 5.2.2.1.1. Stereotactic Radiation Therapy
        • 5.2.2.1.1.1. LINAC
        • 5.2.2.1.1.2. Other Types
      • 5.2.2.1.2. Conventional Radiation Therapy
    • 5.2.2.2. Surgery
    • 5.2.2.3. Chemotherapy
    • 5.2.2.4. Immunotherapy
    • 5.2.2.5. Others
  • 5.2.3. By Cancer Type
    • 5.2.3.1. Skin Cancers
    • 5.2.3.2. Lymphomas
    • 5.2.3.3. Sarcomas
    • 5.2.3.4. Others
  • 5.2.4. By Region
    • 5.2.4.1. North America
    • 5.2.4.2. Europe
    • 5.2.4.3. Asia-Pacific
    • 5.2.4.4. South America
    • 5.2.4.5. Middle East and Africa
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Animal Type
  • 5.3.2. By Therapy
  • 5.3.3. By Cancer Type
  • 5.3.4. By Region

6. North America Veterinary Oncology Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Animal Type
    • 6.2.1.1. Canine
    • 6.2.1.2. Feline
    • 6.2.1.3. Equine
    • 6.2.1.4. Others
  • 6.2.2. By Therapy
    • 6.2.2.1. Radiotherapy
      • 6.2.2.1.1. Stereotactic Radiation Therapy
        • 6.2.2.1.1.1. LINAC
        • 6.2.2.1.1.2. Other Types
      • 6.2.2.1.2. Conventional Radiation Therapy
    • 6.2.2.2. Surgery
    • 6.2.2.3. Chemotherapy
    • 6.2.2.4. Immunotherapy
    • 6.2.2.5. Others
  • 6.2.3. By Cancer Type
    • 6.2.3.1. Skin Cancers
    • 6.2.3.2. Lymphomas
    • 6.2.3.3. Sarcomas
    • 6.2.3.4. Others
  • 6.2.4. By Country Share
    • 6.2.4.1. United States
    • 6.2.4.2. Canada
    • 6.2.4.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Veterinary Oncology Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Animal Type
        • 6.3.1.2.1.1. Canine
        • 6.3.1.2.1.2. Feline
        • 6.3.1.2.1.3. Equine
        • 6.3.1.2.1.4. Others
      • 6.3.1.2.2. By Therapy
        • 6.3.1.2.2.1. Radiotherapy
        • 6.3.1.2.2.1.1. Stereotactic Radiation Therapy
        • 6.3.1.2.2.1.1.1. LINAC
        • 6.3.1.2.2.1.1.2. Other Types
        • 6.3.1.2.2.1.2. Conventional Radiation Therapy
        • 6.3.1.2.2.2. Surgery
        • 6.3.1.2.2.3. Chemotherapy
        • 6.3.1.2.2.4. Immunotherapy
        • 6.3.1.2.2.5. Others
      • 6.3.1.2.3. By Cancer Type
        • 6.3.1.2.3.1. Skin Cancers
        • 6.3.1.2.3.2. Lymphomas
        • 6.3.1.2.3.3. Sarcomas
        • 6.3.1.2.3.4. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Veterinary Oncology Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Veterinary Oncology Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Veterinary Oncology Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Veterinary Oncology Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Supply Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Zoetis Services LLC
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 20.3.2. Merck & Co. Inc.
  • 20.3.3. IDEXX Laboratories, Inc.
  • 20.3.4. Heska Corporation
  • 20.3.5. Dechra Pharmaceuticals Limited
  • 20.3.6. Elanco Animal Health Incorporated
  • 20.3.7. Indian Immunologicals Ltd
  • 20.3.8. Boehringer Ingelheim International GmbH
  • 20.3.9. Hester Biosciences Pvt. Ltd
  • 20.3.10. Virbac Animal Health India Private Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer